The purpose of this study is to determine whether taurolidine with heparin locking solution prevents recurrence of central venous catheter related blood stream infections in haemodialysis patients.
Infections related to long-term haemodialysis catheters are associated with significant morbidity. A high proportion of those people initially treated with antibiotics to clear a catheter infection develop a second infection within six months, necessitating the removal and replacement of the dialysis catheter. This study will examine the efficacy of an antimicrobial catheter locking solution called taurolidine with heparin in preventing a second infection within six months of a significant infection. This solution will be compared with the solution used currently (heparin) which is left inside the catheter between dialysis sessions. This is a clinical study given that antimicrobial catheter locks are thought to reduce the risk of blood stream infections and the ultimate need for catheter change. However, there is concern that the absence of an anticoagulant in the lock solution increases the risk of catheter thrombosis, again requiring a change of catheter but for a separate reason. It is unclear therefore whether a solution containing both taurolidine (an antimicrobial) and heparin (an anticoagulant) will increase catheter survival. The results of this study will help guide the appropriate suse of locking solutions in the future.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
27
Central venous catheter will be locked (the designated volume required to fill the dead space) with taurolidine with heparin after each dialysis session. The control arm will be locked with heparin as is current practice.
Imperial College Healthcare NHS Trust
London, United Kingdom
Duration of bacteraemia-free catheter survival
Time frame: Catheter survival measured up to six months from enrollment date.
Catheter related flow problems
Quantified by use of: 1. Urokinase locks 2. Systemic urokinase infusions
Time frame: Catheter survival measured up to six months from enrollment date.
Hospital admissions for catheter related problems including catheter removal
Time frame: Catheter survival measured up to six months from enrollment date.
Erythropoietin resistance
Quantified by: 1. Erythropoietin dose 2. Number of blood transfusions required
Time frame: Catheter survival measured up to six months from enrollment date.
Haemodialysis adequacy
Quantified by: 1. Kt/V 2. Blood flows
Time frame: Catheter survival measured up to six months from enrollment date.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.